TNFRSF10B and head and neck cancer: Administration of 20 μCi or 100 μCi (2.5 Gy or 12 Gy tumor absorbed dose, respectively) 90Y-NM600 in an immunologically cold syngeneic murine model of head and neck cancer, MOC2, resulted in IFN1 activation and induction of immune susceptibility markers (Fas, Mhc-1, Pd-l1, death receptor 5 (Dr5)) that were comparable to dose equivalent EBRT (2.5 Gy, 12 Gy) treatments in vivo [52].